Fortrea (FTRE) Competitors

Progyny (NASDAQ:PGNY) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Does the media prefer PGNY or FTRE?

In the previous week, Progyny had 2 more articles in the media than Fortrea. MarketBeat recorded 13 mentions for Progyny and 11 mentions for Fortrea. Progyny's average media sentiment score of 1.14 beat Fortrea's score of 0.54 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is PGNY or FTRE more profitable?

Progyny has a net margin of 5.03% compared to Fortrea's net margin of -10.99%. Progyny's return on equity of 11.36% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.03%	11.36%	7.87%
Fortrea	-10.99%	2.00%	0.80%

Does the MarketBeat Community favor PGNY or FTRE?

Progyny received 91 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 70.83% of users gave Progyny an outperform vote while only 22.00% of users gave Fortrea an outperform vote.

Company	Underperform	Outperform
Progyny	Outperform Votes 102 70.83%	Underperform Votes 42 29.17%
Fortrea	Outperform Votes 11 22.00%	Underperform Votes 39 78.00%

Which has stronger earnings and valuation, PGNY or FTRE?

Progyny has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.17B	1.57	$62.04M	$0.57	37.61
Fortrea	$2.70B	0.18	-$3.40M	-$3.69	-1.43

Do analysts rate PGNY or FTRE?

Progyny currently has a consensus price target of $23.64, suggesting a potential upside of 10.24%. Fortrea has a consensus price target of $16.70, suggesting a potential upside of 215.69%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Fortrea	2 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.83

Do institutionals & insiders have more ownership in PGNY or FTRE?

94.9% of Progyny shares are owned by institutional investors. 12.3% of Progyny shares are owned by insiders. Comparatively, 0.1% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, PGNY or FTRE?

Progyny has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Summary

Progyny beats Fortrea on 15 of the 18 factors compared between the two stocks.